We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates.

SAN DIEGO--(BUSINESS WIRE)--CRISPR QC, a pioneering biotechnology company in San Diego, is excited to announce the launch of several groundbreaking products designed to revolutionize the field of gene ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the top gene therapy stocks to buy according to hedge funds. On February 17, ...

CRISPR Therapeutics and Vertex Pharmaceuticals are partners in one particular program, and they recently won approval for the gene-editing treatment Casgevy. Beyond Casgevy, Vertex has a ...

Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...

CRISPR stocks are high risk but hold potential for aggressive investors. CRISPR Therapeutics and its partner Vertex Pharmaceuticals have the only approved CRISPR therapy. Several other biotech ...

JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price target of $74.00. Silvan Tuerkcan has assigned a Buy rating to ...

BRISBANE, Calif.--(BUSINESS WIRE)--Mammoth Biosciences, the biotech company leveraging the diversity of life to build the next generation of CRISPR products to cure and detect disease, today announced ...

Scientific innovations, like the advancements in CRISPR technology, have the potential to reshape entire industries, creating groundbreaking solutions that can advance science, improve lives and even ...

Integrated DNA Technologies (IDT) has introduced a new approach to CRISPR—its innovative Alt-R™ CRISPR-Cas9 System, based on the naturally occurring S. pyogenes CRISPR RNA system. The Alt-R ...